Full Length Versus Proximal Renal Arteries Ablation

NCT ID: NCT01848275

Last Updated: 2017-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Catheter-based renal sympathetic modification has been documented to be effective option for blood pressure control in patients with resistant hypertension, but the safety is still concerned around worldwide. Based on anatomic findings, blocking renal sympathetic nerves at proximity may be enough for successful renal sympathetic modifications. This study was designed to compare the efficacy and safety of full length versus proximal ablation of bilateral renal arteries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After baseline assessment was completed, patients with resistant hypertension were enrolled, and randomly divided into two groups. This study is going to recruit 40 patients (group 1 VS group 2 = 1:1) with a follow-up duration of one year. Group 1 received ablation from distal to ostial of bilateral renal arteries, group 2 received ablation at proximal of bilateral renal arteries. RDN was performed with saline irrigated catheter. Office and ambulatory blood pressure was measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Resistant to Conventional Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Group 1 received ablation from distal to ostial of bilateral renal arteries

Group Type ACTIVE_COMPARATOR

Thermocool®Rcatheter

Intervention Type DEVICE

The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter

Group 2

group 2 received ablation at proximal of bilateral renal arteries

Group Type EXPERIMENTAL

Thermocool®Rcatheter

Intervention Type DEVICE

The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thermocool®Rcatheter

The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter

Intervention Type DEVICE

Thermocool®Rcatheter

The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* office systolic blood pressure of 160 mm Hg or more,
* patients had to be on a stable drug regimen of at least 3 antihypertensive medications with no changes for 1 month before enrollment.
* Despite being treated with at least three antihypertensive drugs(including one diuretic), or confirmed intolerance to medications;
* ≥ 18 years old,;
* did not have any known secondary cause of hypertension;
* had a glomerular filtration rate estimated with the modification of diet in renal disease formula, of 45 ml/min/1.73m2 or more.

Exclusion Criteria

* patients with type 1 diabetes,
* implanted pacemakers or implantable cardioverter defibrillators;
* pregnant women;
* haemodynamically significant valvular disease;
* patients with renovascular abnormalities(including mild to severe renal artery stenosis, especially caused by atherosclerosis, previous renal stenting or angioplasty, or known dual renal arteries, or diameter of renal artery identified by angiography less than 4 mm and/or length of renal artery less than 2 cm)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Second Affiliated Hospital of Chongqing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuehui Yin

Director and Professor, Dept. of Cardiology, the second affiliated hospital of Chongqing Medical University, Chongqing Cardiac arrhythmias service center

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

2ndChongqingMU

Chongqing, Chongqing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SWAN- RDN Strategy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811 ACTIVE_NOT_RECRUITING NA
SMART Study in Real World
NCT06780696 NOT_YET_RECRUITING